241 related articles for article (PubMed ID: 10781189)
1. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
4. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
Mauser-Bunschoten EP; Koopman MM; Goede-Bolder AD; Leebeek FW; van der Meer J; van Marwijk Kooij GM; van der Linden PW;
Haemophilia; 2002 Sep; 8(5):649-56. PubMed ID: 12199674
[TBL] [Abstract][Full Text] [Related]
6. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
7. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
9. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
10. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
11. NovoSeven in immune tolerance therapy.
Brackmann HH; Effenberger E; Hess L; Schwaab R; Oldenburg J
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S39-44. PubMed ID: 10850563
[TBL] [Abstract][Full Text] [Related]
12. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
13. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
[No Abstract] [Full Text] [Related]
14. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Smith OP
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H
Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
Lusher JM; Roberts HR; Davignon G; Joist JH; Smith H; Shapiro A; Laurian Y; Kasper CK; Mannucci PM
Haemophilia; 1998 Nov; 4(6):790-8. PubMed ID: 10028299
[TBL] [Abstract][Full Text] [Related]
17. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
18. Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections.
Scaraggi FA; De Mitrio V; Marino R; Speciale V; Di Bari L; Petronelli M; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Jan; 10(1):33-8. PubMed ID: 10070833
[TBL] [Abstract][Full Text] [Related]
19. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).
Kenet G; Lubetsky A; Luboshitz J; Martinowitz U
J Thromb Haemost; 2003 Mar; 1(3):450-5. PubMed ID: 12871449
[TBL] [Abstract][Full Text] [Related]
20. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
Seremetis S
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
